Quantcast
The Bearish Case for Alnylam Pharmaceuticals (ALNY) | The Mesh Report

The Bearish Case for Alnylam Pharmaceuticals (ALNY)

Christian Tharp, CMT November 20, 2020 Comments Off on The Bearish Case for Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals Inc. (ALNY) is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference (RNAi). The company’s pipeline of solutions is focused across three therapeutic areas: genetic medicines, cardio-metabolic disease, and hepatic infectious disease.

The company recently posted its latest financial results with earnings well under estimates and down year over year, but revenue outperformed and was up 79.6% from the prior year period. While the company has a broad pipeline of therapeutic candidates, most are in the early stages of development.

ALNY has a strong history of revenue growth, but has not had positive income over the last ten years. Though it does have a strong balance sheet with $1.8 billion in cash at the end of the quarter. While its gross margin is 83.2%, its net margin is a negative 222.2%.

The stock has a high valuation, with a Price to Sales ratio of 35.2 and a Price to Book ratio of 11.8. It has shown bearish short and mid-term momentum, but is up for the year. This has led to a “Neutral” rating in our POWR Ratings system, with a grade of D” in Trade Grade.

Take a look at the 1-year chart of ALNY below with the added notations…

See chart and continue reading at STOCKNEWS.com



Comments are closed.